Application of interferon alpha 2b in conjunctival intraepithelial neoplasia: Predictors and prognostic factors

Journal of Ocular Pharmacology and Therapeutics

Volumn 30, Issue 6, 2014, Pages 489-494

  Muñoz De Escalona Rojas, José Enrique ^a   García Serrano, José Luis ^a   Cantero Hinojosa, Jesús ^a   Padilla Torres, José Francisco ^a   Bellido Muñoz, Rosa María ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; EYE DROPS; INTROM A; UNCLASSIFIED DRUG; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; RECOMBINANT PROTEIN;

ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER CYTODIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CHRONOTHERAPY; CLINICAL ARTICLE; CONJUNCTIVA TUMOR; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVAL INTRAEPITHELIAL NEOPLASIA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; FOLLICULAR HYPERTROPHY; GIANT PAPILLARY CONJUNCTIVITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMPRESSION CYTOLOGY; INTERFERON INDUCTION; INTERVENTION STUDY; MALE; PRECANCER AND CANCER-IN-SITU; PREDICTIVE VALUE; PROSPECTIVE STUDY; PUNCTATE KERATITIS; SLIT LAMP; TOPICAL TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; CARCINOMA IN SITU; CLINICAL TRIAL; CONJUNCTIVAL NEOPLASMS; FOLLOW UP; INTRAOCULAR DRUG ADMINISTRATION; MIDDLE AGED; OPHTHALMOSCOPY; PATHOLOGY; PROCEDURES; PROGNOSIS; RISK FACTOR; TIME; TREATMENT OUTCOME; ULTRAVIOLET RADIATION; VERY ELDERLY;

ADMINISTRATION, OPHTHALMIC; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA IN SITU; CONJUNCTIVAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OPHTHALMOSCOPY; PROGNOSIS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RISK FACTORS; SLIT LAMP; TIME FACTORS; TREATMENT OUTCOME; ULTRAVIOLET RAYS;

EID: 84903720641     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2013.0084     Document Type: Article

References (21)

1. Shields, J.A., and Shields, C.L. Premalignant and malignant lesions of the conjunctival epithelium. In: Eyelid, Con-junctival, and Orbital Tumors: An Atlas and Textbook. Philadelphia: Lippincott Williams & Wilkins; 2008; pp. 283-305.
2. Rahimi, F., Alipour, F., Hashemi, H., et al. Topical mitommycin-C for treatment of partially-excised ocular surface squamous neoplasia. Arch. Iranian. 12:55-59, 2009.
3. Erie, J.C., Campbell, R.J., and Liesegang, T.J. Conjunctival and corneal intraepithelial and invasive neoplasia. Ophthalmology. 93:176-183, 1986.
4. Fraunfelder, F.T., and Wingfield, D. Management of in-traepitehelial conjunctival tumors and squamous cell carcinomas. Am. J. Ophthalmol. 95:359-363, 1983.
5. Frucht-Pery, J., Rozenman, Y., and Peler, J. Topical my-tomycin-C for partially excised conjunctival squamous cell carcinoma. Ophthalmology. 109:548-552, 2002.
6. Birkhotz, E.S., Goins, K.M., Sutphin, J.E., et al. Treatment of ocular surface squamous cell intraepithelial neo-plasia with and without mitomycin C. Cornea. 30:37-41, 2011.
7. Russell, H.C., Chadha, V., Lockington, D., and Kemp, E.G. Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications. Br. J. Ophthalmol. 94:1316-1321, 2010.
8. Huerva, V., and Mangues, I. Treatment of conjunctival squamous neoplasias with interferon alpha 2b. J. Fr. Oph-talmol. 31:317-325, 2008.
9. Sturges, A., Butt, A.L., Lai, J.E., et al. Topical interferon or surgical excision for the management of primary ocular surface squamous neoplasia. Ophthalmology. 115:1297-1302, 2008.
10. Schechter, B.A., Koreishi, A.F., Karp, C.L., et al. Long-term follow-up of conjunctival and corneal intraepithelial neoplasia treated with topical interferon alpha-2b. Ophthalmology. 115:1291-1296, 2008.
11. Shields J.A., Shields C.L. Premalignant and malignant lesions of the conjunctival epithelium. Eyelid, Con-junctival, and Orbital Tumors: An Atlas and Textbook. Philadelphia: Lippincott Williams & Wilkins; 2008; pp. 283-305.
12. Edge, S.B., Byrd, D.R., Compton, C.C., et al. Carcinoma of the Conjunctiva. AJCC Cancer Staging Manual 7th ed. New York: Springer; 2010; pp. 531-537.
13. Kim, H.J., Shields, C.L., Shah, S.U., et al. Giant ocular surface squamous neoplasia managed with interferon alpha-2b as an immunotherapy or immunoreduction. Ophthalmology. 119:938-944, 2012.
14. Fuchsluger, T.A., Hintschich, C., Steuhl, K.P., et al. Adjuvant topical interferon-alpha-2b treatment in epithelial tumors of the ocular surface. Ophthalmologe. 103:124-128, 2006.
15. Boehm, M.D., and Huang, A.J. Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b. Ophthalmology. 111:1755-1761, 2004.
16. Karp, C.L., Galor, A., Chhabra, S., Barnes, S.D., and Alfonso, E.C. Subconjunctival/perilesional recombinant interferon a2b for ocular surface squamous neoplasia: a 10-year review. Ophthalmology. 117:2241-2246, 2010.
17. Yousef, Y.A., and Finger, P.T. Squamous carcinoma and dysplasia of the conjunctiva and cornea: an analysis of 101 cases. Ophthalmology. 119:233-240, 2012.
18. Baron, S., Tyring, S.K., Fleischmann, W.R. Jr., et al. The interferons: mechanism of action and clinical applications. JAMA. 266:1375-1383, 1991.
19. Karp, C.L., Moore, J.K., and Rosa, R.H., Jr. Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b. Ophthalmology.108:1093-1098, 2001.
20. Ateenvi-Agaba, C., Dai, M., Le Calvez, F., Katongole-Mbidge, E., et al. TP53 mutations in squamous-cell carcinomas of the conjunctiva: evidence for UV-induced mutagenesis. Mutagenesis. 19:399-401, 2004.
21. Huerva, V., Sánchez, M.C., and Manques, I. Tumor-volume increase at beginning of primary treatment with topical interferon alpha 2-beta in a case of conjunctiva-cornea in-traepithelial neoplasia. J. Ocul. Pharmacol. Ther. 23:143-145, 2007.